-
![BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2019/03/28/US20190092762A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190092762A1
公开(公告)日：2019-03-28
申请号：US16199489
申请日：2018-11-26
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Aleksandra Rudnitskaya , David R. Lancia, JR.
IPC: C07D413/06 , C07D267/22
CPC classification number: C07D413/06 , C07D267/22
Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: where R, L, X1, X2, X3, X4, X5, Y1, Y2, Y3, and Y4 are described herein.
-
![3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/03/26/US10239845B2/abs.jpg.150x150.jpg)
公开(公告)号：US10239845B2
公开(公告)日：2019-03-26
申请号：US15013816
申请日：2016-02-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin
IPC: A61K31/553 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
公开(公告)号：US20180297939A1
公开(公告)日：2018-10-18
申请号：US15925559
申请日：2018-03-19
Applicant: FORMA Therapeutics, Inc.
Inventor： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng
IPC: C07C259/06 , C07D471/04 , C07D417/04 , C07D241/08 , C07D213/56 , C07D233/68 , C07D235/14 , C07D487/10 , C07D471/10 , C07D295/155 , C07D209/44 , A61K31/5377 , A61K31/4439 , A61K31/495 , A61K31/44 , A61K31/417 , A61K31/4184 , A61K31/397 , C07D495/10 , A61K31/407 , A61K31/435 , A61K31/451 , A61K31/4035 , A61K31/277 , A61K31/438 , C07D221/20 , A61K31/185 , C07D307/68 , C07D213/65 , C07D295/192 , C07D211/58 , C07D211/16 , C07D513/10 , C07D209/46 , C07D209/42 , C07D277/56 , C07D209/08 , C07D498/04 , C07D207/267 , C07D493/08 , C07D207/10 , C07D491/10 , C07D487/08 , C07D487/04 , C07D261/18 , C07D257/04 , C07D249/18 , C07D417/12 , C07D241/12 , C07D409/12 , C07D409/04 , C07D405/12 , C07D239/22 , C07D239/20 , C07D235/30 , C07D401/12 , C07D401/04 , C07D333/70 , C07D233/38 , C07D233/36 , C07D231/18 , C07D231/14 , C07D317/68 , C07D215/12 , C07D213/81 , C07D213/75 , C07D401/14
CPC classification number: C07C259/06 , A61K31/185 , A61K31/277 , A61K31/397 , A61K31/4035 , A61K31/407 , A61K31/417 , A61K31/4184 , A61K31/435 , A61K31/438 , A61K31/44 , A61K31/4439 , A61K31/451 , A61K31/495 , A61K31/5377 , C07D207/10 , C07D207/267 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/46 , C07D211/16 , C07D211/58 , C07D213/56 , C07D213/65 , C07D213/75 , C07D213/81 , C07D215/12 , C07D221/20 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D233/68 , C07D235/14 , C07D235/30 , C07D239/20 , C07D239/22 , C07D241/08 , C07D241/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D277/56 , C07D295/155 , C07D295/192 , C07D307/68 , C07D317/68 , C07D333/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D493/08 , C07D495/10 , C07D498/04 , C07D513/10 , Y02A50/393 , Y02A50/411 , Y02A50/481
Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
-
公开(公告)号：US09630922B2
公开(公告)日：2017-04-25
申请号：US15130613
申请日：2016-04-15
Applicant: Forma Therapeutics, Inc.
Inventor： Pui Yee Ng , Heather Davis , Kenneth W. Bair , David S. Millan , Aleksandra Rudnitskaya , Xiaozhang Zheng , Bingsong Han , Nicholas Barczak , David R. Lancia, Jr.
IPC: C07D221/20 , C07D403/04 , C07D209/96 , C07D401/04 , C07D417/06 , C07D519/00 , C07D401/06 , C07D413/06 , C07D405/04 , C07D471/04 , C07D497/10 , C07D491/107 , C07D405/06 , C07D403/06 , C07D405/10
CPC classification number: C07D209/96 , C07D221/20 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/06 , C07D417/06 , C07D471/04 , C07D491/107 , C07D497/10 , C07D519/00
Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
-
![[6,6] FUSED BICYCLIC HDAC8 INHIBITORS](/abs-image/US/2017/03/09/US20170066729A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170066729A1
公开(公告)日：2017-03-09
申请号：US15255817
申请日：2016-09-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Thomason , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair
IPC: C07D265/36 , C07D413/06 , C07D401/04 , C07D279/16 , C07D265/34 , C07D413/10 , C07D471/04 , C07D417/06 , C07D513/04 , C07D487/04 , C07D413/12 , C07D491/107
CPC classification number: C07D265/36 , C07D265/34 , C07D279/14 , C07D279/16 , C07D401/04 , C07D413/06 , C07D413/10 , C07D413/12 , C07D417/06 , C07D471/04 , C07D487/04 , C07D491/107 , C07D513/04
Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，前药，溶剂合物，水合物，互变异构体或异构体，其中R1，R2，R2'，L，X，W，Y1，Y2，Y3和 Y4。
-
Patent Agency Ranking
公开(公告)号：US20160304462A1
公开(公告)日：2016-10-20
申请号：US15130613
申请日：2016-04-15
Applicant: Forma Therapeutics, Inc.
Inventor： Pui Yee Ng , Heather Davis , Kenneth W. Bair , David S. Millan , Aleksandra Rudnitskaya , Xiaozhang Zheng , Bingsong Han , Nicholas Barczak , David R. Lancia, JR.
IPC: C07D221/20 , C07D403/04 , C07D209/96 , C07D401/04 , C07D417/06 , C07D519/00 , C07D401/06 , C07D413/06 , C07D405/04 , C07D471/04 , C07D497/10 , C07D491/107 , C07D405/06 , C07D403/06
CPC classification number: C07D209/96 , C07D221/20 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/06 , C07D417/06 , C07D471/04 , C07D491/107 , C07D497/10 , C07D519/00
Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Abstract translation: 本发明涉及组蛋白脱乙酰酶（HDAC）如HDAC6的抑制剂及其在治疗诸如细胞增殖性疾病（例如癌症），神经系统疾病（例如神经变性疾病或神经发育疾病），炎性或自身免疫性疾病 疾病，感染，代谢疾病，血液病或心血管疾病。
-
公开(公告)号：US20200331847A1
公开(公告)日：2020-10-22
申请号：US16689252
申请日：2019-11-20
Applicant: FORMA Therapeutics, Inc.
Inventor： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng
IPC: C07C259/06 , A61K31/185 , C07D221/20 , A61K31/438 , A61K31/277 , C07D209/44 , A61K31/4035 , C07D295/155 , A61K31/451 , C07D471/10 , A61K31/435 , C07D487/10 , A61K31/407 , C07D495/10 , A61K31/397 , C07D235/14 , A61K31/4184 , C07D233/68 , A61K31/417 , C07D213/56 , A61K31/44 , C07D241/08 , A61K31/495 , C07D417/04 , A61K31/4439 , A61K31/5377 , C07D471/04 , C07D401/14 , C07D213/75 , C07D213/81 , C07D215/12 , C07D317/68 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D333/70 , C07D401/04 , C07D401/12 , C07D235/30 , C07D239/20 , C07D239/22 , C07D405/12 , C07D409/04 , C07D409/12 , C07D241/12 , C07D417/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D487/04 , C07D487/08 , C07D491/10 , C07D207/10 , C07D493/08 , C07D207/267 , C07D498/04 , C07D209/08 , C07D277/56 , C07D209/42 , C07D209/46 , C07D513/10 , C07D211/16 , C07D211/58 , C07D295/192 , C07D213/65 , C07D307/68
Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
-
公开(公告)号：US20200017525A1
公开(公告)日：2020-01-16
申请号：US16077407
申请日：2017-02-13
Applicant: FORMA Therapeutics, Inc.
Inventor： David Joseph Guerin , Kenneth W. Bair , Justin A. Caravella , Stephanos Ioannidis, Jr. , David R. Lancia, Jr. , Hongbin Li , Steven Mischke , Pui Yee Ng , David Richard , Shawn E.R. Schiller , Tatiana Shelekhin , Zhongguo Wang
IPC: C07D519/00 , C07D495/04
Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, R7, X, m, and n are described herein.
-
![3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2020/01/02/US20200002298A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200002298A1
公开(公告)日：2020-01-02
申请号：US16567007
申请日：2019-09-11
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC: C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D267/12 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/11/19/US10479772B2/abs.jpg.150x150.jpg)
公开(公告)号：US10479772B2
公开(公告)日：2019-11-19
申请号：US16220035
申请日：2018-12-14
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin
IPC: A61K31/553 , C07D498/04 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
-
-
-
-
-
-
-
-
Search Results
76
records
(took 0.039 seconds)
